In five patients, anti-cancer therapy was resumed, including three patients treated with a CDK4/6 inhibitor (abemaciclib n = 2 and palbociclib n = 1), with follow-up between 72 and 212 days without hepatitis recurrence. This evidence concerns the gene CDK4 and cancer.